You receive your blood test results and one number catches your attention: the CA 19-9 level exceeds the reference value. Before thinking the worst, know that this tumor marker can increase for very varied reasons, sometimes with no connection to cancer. Understanding why the CA 19-9 antigen level increases allows for a clearer approach to the subsequent medical journey.
Lewis Status: When Genetics Distorts the Interpretation of CA 19-9
CA 19-9, also known as sialyl Lewis-a, is a protein produced by the cells of the pancreas, liver, and gallbladder. Its production depends on a factor rarely mentioned in test results: Lewis status.
The Lewis antigen is a genetic marker present on the surface of cells. About 10% of the population simply does not produce CA 19-9, regardless of their health status. In these individuals, a normal level does not mean the absence of disease. Pancreatic cancer can progress without any change in CA 19-9.
Conversely, a person who produces a lot of this antigen may show a level slightly above the threshold without any serious pathology. That’s why an isolated result is never enough to make a diagnosis. To better understand the causes of elevated CA 19-9 antigen, this measurement should always be cross-referenced with other tests and the patient’s clinical context.
Benign Causes of Elevated CA 19-9: Non-Cancerous Diseases
An elevated CA 19-9 level does not necessarily indicate cancer. Several benign conditions can cause this increase, sometimes significantly.
Liver and Biliary Disorders
Liver and biliary tract diseases are among the most common causes of elevation without a tumor. A biliary obstruction (stone, inflammation) disrupts the drainage of bile. CA 19-9, normally present in small amounts, then accumulates in the blood.
A cholangitis or biliary lithiasis can raise the level well above the reference threshold. The doctor will then refer for imaging (ultrasound, CT scan) to identify the cause of the obstruction.
Pancreatic Diseases Other Than Cancer
A pancreatitis, whether acute or chronic, stimulates the production of CA 19-9 by inflamed pancreatic cells. The level generally decreases after the resolution of the inflammatory episode.
Uncontrolled Diabetes and Metabolic Disorders
This is a lesser-known angle. Poorly controlled diabetes can lead to a mild to moderate elevation of CA 19-9, with no link to a tumor. The level then exceeds the reference threshold but remains below the very high values observed in advanced cancers.
If you are diabetic and your CA 19-9 is slightly above normal, your doctor will first check your glycemic control before considering further investigations.
Pulmonary Disorders
Respiratory conditions such as bronchiectasis (chronic dilation of the bronchi) can also cause an increase in CA 19-9. A clinical case published in the Revue des Maladies Respiratoires describes a patient whose high level triggered an oncological assessment before the pulmonary cause was identified.
In summary, benign situations responsible for an increase in CA 19-9 include:
- Biliary tract obstructions and inflammations (lithiasis, cholangitis)
- Acute or chronic pancreatitis, which directly irritates the CA 19-9 producing tissue
- Uncontrolled diabetes and certain metabolic syndromes, an underestimated cause
- Chronic pulmonary diseases, particularly bronchiectasis
Cancers Associated with an Increase in CA 19-9 Levels
When the CA 19-9 level rises significantly, the doctor primarily looks for certain cancers. This tumor marker is mainly used in the follow-up of two types of tumors.
Pancreatic Cancer
CA 19-9 is the most commonly used serological marker for pancreatic cancer. A very high level, associated with symptoms (weight loss, abdominal pain, jaundice), leads to a thorough assessment: abdominal CT scan, MRI, sometimes endoscopic ultrasound performed by a gastroenterologist.
The measurement is also used to monitor treatment response. If the level decreases after surgery or chemotherapy, it is a favorable signal. If it rises again, the oncologist suspects a recurrence.
Biliary Tract Cancer
Cholangiocarcinomas (biliary duct cancers) also cause increased production of CA 19-9. The surgeon and oncologist rely on this marker, combined with imaging, to adapt the therapeutic strategy.
Other Cancers
CA 19-9 can increase in other digestive cancers: stomach, colon, rectum. The elevation is often more modest than in pancreatic cancers. This measurement is not the reference marker for these locations, but it sometimes complements the assessment.
Limitations of CA 19-9: Why This Marker Is Not Sufficient for Diagnosis
The CA 19-9 measurement cannot be used alone for cancer screening. The reasons are specific:
- About 5 to 22% of people do not produce CA 19-9 (negative Lewis status), making the test useless for them
- Many benign diseases (liver, biliary, pancreatic, pulmonary, metabolic) cause false positives
- A normal level does not exclude an early cancer, especially in non-genetic producers
A CA 19-9 result is always interpreted with the complete clinical context: symptoms, imaging results, other blood tests. Your primary care physician or gastroenterologist remains the only person capable of making sense of this number.
In practice, a level slightly above normal in a symptom-free person often leads to a follow-up a few weeks later, not a cancer diagnosis. The trend of the level over time matters more than a single value. A CA 19-9 that steadily increases during successive measurements is more concerning than an isolated spike that spontaneously decreases.